Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.

Tejas Patil,David Chun Cheong Tsui,Andrew Nicklawsky,Erin L. Schenk,William T. Purcell,Paul A. Bunn,Jose Maria Pacheco,D. Ross Camidge

Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.

2021

Tejas Patil
David Chun Cheong Tsui
Andrew Nicklawsky
Erin L. Schenk
William T. Purcell
Paul A. Bunn
Jose Maria Pacheco
D. Ross Camidge

9124Background: Continuing a 1st generation EGFR TKI with chemotherapy upon TKI progression was not shown to be beneficial in the IMPRESS trial. However, the validity of this approach with osimerti...

Keywords:

Epidermal growth factor receptor
Internal medicine
Medicine
egfr tki
Osimertinib
Oncology
Chemotherapy
EGFR positive non-small cell lung cancer
Progression-free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations